AzTrials
AzTrials

Stress Disorders, Post-TraumaticCARE4PTSDNCT05244564

Computer Monitor vs Augmented Reality 3MDR for PTSD PTSD: A Randomized Controlled Trial

A study testing Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) in people with Stress Disorders, Post-Traumatic, run by Uniformed Services University of the Health Sciences at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a prospective randomized controlled trial comparing two ways of delivering Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) therapy for posttraumatic stress disorder (PTSD). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Stress Disorders, Post-Traumatic
What is being tested?
Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteUnited States
Study dates
30 Apr 2023to 30 Oct 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Service member, veteran, retiree, or DEERS-eligible dependent, male or female, at least 18 years or older
  • Diagnosis of PTSD, as confirmed by the CAPS-5
  • Able to ambulate with contact guard assistance or less, and walk unassisted on a treadmill, at a normal pace, for up to 90 minutes continuously

Who cannot join

  • History of epilepsy or a seizure disorder, other than febrile seizures that occurred during childhood and have not recurred since
  • History of a psychotic disorder, bipolar disorder, or active suicidal or homicidal ideation
  • Use of benzodiazepines on a regular basis within the previous 30 days

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Hannah Attalah, BA contact

301-412-8187

care4ptsd@gmail.com

Michael Roy, MD, MPH contact

301-295-9601

michael.roy@usuhs.edu

United States1 site, 1 recruiting
  • Uniformed Services University

    Bethesda, Maryland, 20814

    Paula Bellini, MA, 703-463-0289, paula.bellini.ctr@usuhs.edu

    Recruiting

Other trials in United States

About this study

Official title: Computer Monitor Versus Augmented Reality: Expanding 3MDR Therapy for PTSD

This is a prospective randomized controlled trial comparing two ways of delivering Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) therapy for posttraumatic stress disorder (PTSD). The study seeks 60 volunteers who have PTSD and are eligible for care in the Department of Defense healthcare system. There will be 10-14 therapy sessions that are 60-90 minutes long, about once a week, and symptoms will be assessed before and after the therapy as well as 3 and 6 months after completing therapy. 3MDR asks you to choose pictures and music that are integrated into a virtual reality environment. You will be walking on a treadmill throughout each therapy session, while the therapist stands next to the treadmill and asks you questions about the pictures you chose.

Read the detailed description

Posttraumatic stress disorder (PTSD) frequently occurs after combat and other life-threatening or traumatic events. Currently available treatments for PTSD often have a brief, limited effect, or are not well-tolerated. Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) is a new and unique treatment for PTSD that has been commonly referred to as "walk and talk" therapy, because you walk on a treadmill as you work through your symptoms with a therapist. 3MDR also combines some features of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR), and has usually been conducted in the Computer Assisted Rehabilitation Environment (CAREN), a sophisticated virtual reality "cave". Previous clinical studies by us and others across several nations have proven the effectiveness of the 3MDR approach in treating symptoms of PTSD. However, the CAREN is large, expensive (~$1 million), and only available in a few places around the world. To try to make 3MDR available to more people, this study will compare how much PTSD symptoms change with 3MDR delivered via two different mechanisms: 1) walking on a regular treadmill while wearing goggles (known as augmented reality head-mounted display, or AR HMD, specifically the Microsoft Hololens2) that allow you to see the treadmill and things around you in the real world, while also seeing pictures in a virtual world, with 2) walking on the same treadmill, with presentation of pictures on a 34-inch curved high definition gaming computer monitor positioned at eye level directly in front of the treadmill. There will be a total of 60 participants in the study, all at Uniformed Services University. After completing the informed consent process, all participants will be evaluated to confirm that they meet criteria for PTSD. There will be two introductory sessions where you meet the therapist you will be working with, and they will help you choose music and pictures that will be used in your later sessions. These introductory sessions can be done in person or virtually. In the third session you will try walking on the treadmill with a sample picture, via either the AR HMD or the computer monitor, depending on which approach you are randomized to receive-you have an equal chance of either. Starting with the 4th session, you will be talking through the pictures you have chosen, with your therapist. You will spend about 10 minutes on each picture, and do 5 or 6 pictures each session, and will do this through session 9. After that, you will complete a brief questionnaire about your symptoms. If you still have significant symptoms, you will do another 2 sessions of talking through your pictures, then do another questionnaire, and again will do two more sessions if you still have symptoms. There is then one final wrap-up session, which can be done either in person or virtually, to discuss how you did with the therapy, and whether you might need any more therapy to help you if you have any symptoms left to address. Depending on how quickly your symptoms improve, you may do a total of 10, 12 or 14 therapy sessions in this study. After you have finished the therapy sessions, you will again be assessed to see how much your symptoms have improved, and you will do this again 3 and 6 months later.

Being tested
Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)
Medical subject headings
Stress Disorders, Post-Traumatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)Other

    "Walk and talk" therapy, walking on a treadmill while talking with a therapist about self-chosen pictures representative of one's trauma; 3MDR also includes some features of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR) therapy.

Study groups in NCT05244564
Study groupRoleWhat they receive
3MDR delivered via Augmented Reality Head Mounted DisplayExperimentalAll participants will complete 10-14 treatment sessions (three preparatory sessions, 6 to 10 3MDR therapy sessions, and one concluding session), led by a therapist who has completed training and/or is experienced in the conduct of this form of therapy.
Receives: Other: Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)
3MDR delivered via 34-inch curved screen high definition gaming computer monitorActive comparatorAll participants will complete 10-14 treatment sessions (three preparatory sessions, 6 to 10 3MDR therapy sessions, and one concluding session), led by a therapist who has completed training and/or is experienced in the conduct of this form of therapy.
Receives: Other: Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinician Administered PTSD scale for DSM5 (CAPS-5)

    The primary outcome measure will be the Clinician Administered PTSD scale for DSM5 (CAPS-5), the gold standard measure for PTSD diagnosis, to assess PTSD symptom severity.

    Measured: 3 months

  2. PTSD Checklist for DSM5 (PCL5)

    The PTSD Checklist for DSM5 (PCL5), a well-validated 20-item self-report measure of PTSD symptom severity.

    Measured: 3 months

Secondary outcomes (4)
  1. Patient Health Questionnaire Depression module (PHQ-9)

    The Patient Health Questionnaire Depression module (PHQ-9) is a well-validated instrument for assessing depression symptom severity.

    Measured: 3 months

  2. Insomnia Severity Index (ISI)

    The Insomnia Severity Index (ISI) is a validated method with which to evaluate insomnia and sleep difficulties.

    Measured: 3 months

  3. Neurobehavioral Symptom Inventory (NSI)

    The Neurobehavioral Symptom Inventory (NSI) is a validated instrument for assessing postconcussive symptom severity.

    Measured: 3 months

  4. Brief Resilience Scale (BRS)

    The Brief Resilience Scale (BRS) is a validated instrument used to assess resilience.

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Feb 2022
  2. Study start30 Apr 2023
  3. Primary completion31 May 2027 (estimated)
  4. Study completion30 Oct 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
All receive the 3MDR intervention, but are randomized to delivery via AR HMD vs via curved high definition gaming computer monitor
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05244564
Sponsor's protocol ID
USUHS.2021-076
Acronym
CARE4PTSD
Status last verified
Jul 2025
First submitted
11 Aug 2021
Last updated
15 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) in people with Stress Disorders, Post-Traumatic, run by Uniformed Services University of the Health Sciences at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 15 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Hannah Attalah, BA (301-412-8187, care4ptsd@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinician Administered PTSD scale for DSM5 (CAPS-5) (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in